Literature DB >> 19919846

HPMA copolymers: origins, early developments, present, and future.

Jindrich Kopecek1, Pavla Kopecková.   

Abstract

The overview covers the discovery of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers, initial studies on their synthesis, evaluation of biological properties, and explorations of their potential as carriers of biologically active compounds in general and anticancer drugs in particular. The focus is on the research in the authors' laboratory - the development of macromolecular therapeutics for the treatment of cancer and musculoskeletal diseases. In addition, the evaluation of HPMA (co)polymers as building blocks of modified and new biomaterials is presented: the utilization of semitelechelic poly(HPMA) and HPMA copolymers for the modification of biomaterial and protein surfaces and the design of hybrid block and graft HPMA copolymers that self-assemble into smart hydrogels. Finally, suggestions for the design of second-generation macromolecular therapeutics are portrayed. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19919846      PMCID: PMC2836498          DOI: 10.1016/j.addr.2009.10.004

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  153 in total

1.  Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes.

Authors:  V Omelyanenko; P Kopecková; R K Prakash; C D Ebert; J Kopecek
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

2.  Synthesis of bioadhesive lectin-HPMA copolymer-cyclosporin conjugates.

Authors:  Z R Lu; S Q Gao; P Kopecková; J Kopecek
Journal:  Bioconjug Chem       Date:  2000 Jan-Feb       Impact factor: 4.774

3.  Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells.

Authors:  T Minko; P Kopecková; J Kopecek
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

4.  Polymerizable Fab' antibody fragments for targeting of anticancer drugs.

Authors:  Z R Lu; P Kopecková; J Kopecek
Journal:  Nat Biotechnol       Date:  1999-11       Impact factor: 54.908

5.  High-molecular weight HPMA copolymer-adriamycin conjugates.

Authors:  M Dvorák; P Kopecková; J Kopecek
Journal:  J Control Release       Date:  1999-08-05       Impact factor: 9.776

6.  Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line.

Authors:  T Minko; P Kopecková; J Kopecek
Journal:  J Control Release       Date:  1999-05-20       Impact factor: 9.776

7.  Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma.

Authors:  T Minko; P Kopecková; J Kopecek
Journal:  Int J Cancer       Date:  2000-04-01       Impact factor: 7.396

8.  Cooperativity between free and N-(2-hydroxypropyl) methacrylamide copolymer bound adriamycin and meso-chlorin e6 monoethylene diamine induced photodynamic therapy in human epithelial ovarian carcinoma in vitro.

Authors:  J M Lu; C M Peterson; J Guo-Shiah; Z W Gu; C A Peterson; R C Straight; J Kopecek
Journal:  Int J Oncol       Date:  1999-07       Impact factor: 5.650

9.  Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e(6) and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts.

Authors:  J J Shiah; Y Sun; C M Peterson; J Kopecek
Journal:  J Control Release       Date:  1999-08-27       Impact factor: 9.776

10.  Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours.

Authors:  A H Thomson; P A Vasey; L S Murray; J Cassidy; D Fraier; E Frigerio; C Twelves
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more
  122 in total

1.  HPMA-PLGA Based Nanoparticles for Effective In Vitro Delivery of Rifampicin.

Authors:  Sarita Rani; Avinash Gothwal; Pawan K Pandey; Devendra S Chauhan; Praveen K Pachouri; Umesh D Gupta; Umesh Gupta
Journal:  Pharm Res       Date:  2018-12-03       Impact factor: 4.200

2.  Investigation into the Biological Impact of Block Size on Cathepsin S-Degradable HPMA Copolymers.

Authors:  Wei Fan; Wenting Zhang; Yinnong Jia; Susan K Brusnahan; Jered C Garrison
Journal:  Mol Pharm       Date:  2017-03-21       Impact factor: 4.939

Review 3.  Imaging and drug delivery using theranostic nanoparticles.

Authors:  Siti M Janib; Ara S Moses; J Andrew MacKay
Journal:  Adv Drug Deliv Rev       Date:  2010-08-13       Impact factor: 15.470

Review 4.  Strategies in the design of nanoparticles for therapeutic applications.

Authors:  Robby A Petros; Joseph M DeSimone
Journal:  Nat Rev Drug Discov       Date:  2010-07-09       Impact factor: 84.694

5.  Big thinking for adjuvants.

Authors:  Eric L Dane; Darrell J Irvine
Journal:  Nat Biotechnol       Date:  2015-11       Impact factor: 54.908

6.  Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.

Authors:  Kirk D Fowers; Jindřich Kopeček
Journal:  Macromol Biosci       Date:  2012-01-25       Impact factor: 4.979

7.  Biological activity of anti-CD20 multivalent HPMA copolymer-Fab' conjugates.

Authors:  Russell N Johnson; Pavla Kopečková; Jindřich Kopeček
Journal:  Biomacromolecules       Date:  2012-02-21       Impact factor: 6.988

8.  Synthesis of Biodegradable Multiblock Copolymers by Click Coupling of RAFT-Generated HeterotelechelicPolyHPMA Conjugates.

Authors:  Jiyuan Yang; Kui Luo; Huaizhong Pan; Pavla Kopečková; Jindřich Kopeček
Journal:  React Funct Polym       Date:  2011-03-01       Impact factor: 3.975

9.  HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.

Authors:  Yan Zhou; Jiyuan Yang; Johng S Rhim; Jindřich Kopeček
Journal:  J Control Release       Date:  2013-09-14       Impact factor: 9.776

10.  Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel.

Authors:  Yan Zhou; Jiyuan Yang; Rui Zhang; Jindřich Kopeček
Journal:  Eur J Pharm Biopharm       Date:  2014-12-03       Impact factor: 5.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.